

Chapter IV

Working parties of the Scientific Board

1

Organisation

The French National Observatory for Epidemiology of Bacterial Resistance to Antibiotics (ONERBA) was founded in 1997 in order to:

- gather and analyse data regarding bacterial resistance to antibiotics in France, and to compare these data with those obtained in other countries;
- provide data regarding bacterial resistance to antibiotics to Health Authorities, Scientific Organisations, and Health Professionals, upon request;
- promote quality data collection and analysis;
- initiate research on less documented issues of public interest;
- participate in training activities associated with the issues noted above, particularly by means of presentations and publications.

In order to meet these objectives, a Scientific Board (SB) was created in 1997. A part of the members of this SB was renewed in 2003 as recommended in ONERBA's statutes. The activities of the SB and its relationship with the networks are described in the charter of the networks represented in the SB of ONERBA (see chapter V). The Scientific Board meets during regular working parties in order to:

- select the topics of interest;
- define methods for collection and analysis;
- analyse and validate data;
- implement specific studies.

2

Calendar of the working parties of the Scientific Board in 2003

January, 7;
February, 12;
March, 12-13;
April, 28;
May, 29;
June, 24;
October, 15.

A detailed report of the working parties can be found in the French version of the annual report (www.onerba.org).

3

Sessions organised by ONERBA in National Meetings in 2003

■ Journées Nationales d'Infectiologie (JNI)

ONERBA-JNI 2002 : La surveillance en réseau au service de la prescription

Network of surveillance for improving antibiotic prescription

- Microbiologie et résumé des caractéristiques du produit (RCP) pour les antibiotiques (J.D. Cavallo)
Microbiology and Summary of Product Characteristics for antibiotics
- Surveillance de la résistance et prescription probabiliste (M.H. Nicolas-Chanoine)
Surveillance of bacterial resistance and probabilistic prescription
- La politique de gestion des antibiotiques et les effets qu'ils induisent (V. Jarlier, P. Choutet)
Antibiotic policies and their impact
- Bactéries multirésistantes aux antibiotiques : quels indicateurs pour quelles décisions? (E. Varon, J. Robert)
Multidrug-resistant bacteria: choice of indicators related to objectives

■ Réunions interdisciplinaires de chimiothérapies anti-infectieuses (RICAI)

ONERBA - RICAI 2002 : Résistance bactérienne aux fluoroquinolones

Bacterial resistance to fluoroquinolones

- Consommation des quinolones en France (P. Choutet)
Quinolone use in France
- Bactéries entéropathogènes pour l'homme et l'animal (D. Meunier)
Enteropathogenic bacteria in human and animals
- Pathogènes communautaires : l'exemple de *Haemophilus influenzae* et *Escherichia coli* (P. Laudat)
Pathogens in the community: the example of Haemophilus influenzae and Escherichia coli

CHAPTER IV

- Pathogènes naturellement résistants aux quinolones classiques : l'exemple de *Staphylococcus aureus* et de *Pseudomonas aeruginosa* (R. Fabre)
Pathogens naturally resistant to classical quinolones: the example of Staphylococcus aureus and Pseudomonas aeruginosa
- Résistance bactérienne aux fluoroquinolones : conclusion
Bacterial resistance to fluoroquinolones: conclusion

4

Participation of ONERBA to other meetings

- XIVth Meeting of the French Society of Hospital Hygiene**
Séance plénière 3 : La maîtrise de la résistance aux antibiotiques
Plenary session 3: Mastering antibiotic resistance
Épidémiologie de la résistance
Epidemiology of bacterial resistance (V. Jarlier).

5

Publications of ONERBA

- Fluoroquinolones et flore digestive résistante en réanimation [enquête transréseaux ONERBA] (Fluoroquinolones and digestive bacterial flora in intensive care units). J. Robert. *Med Mal Infect* 2003;33(suppl.B):39.
- Fluoroquinolones et pneumocoques (Fluoroquinolones and pneumococci). E. Varon, L. Gutmann. *Med Mal Infect* 2003;33(suppl.B):40-1.
- État des résistances bactériennes aux fluoroquinolones en médecine humaine et vétérinaire en France (Bacterial resistance to fluoroquinolones in human and veterinary medicine in France). V. Jarlier. *Med Mal Infect* 2003;33(suppl.B):41-4.

6

Publications of the Networks Federated in ONERBA

- Dubois V, Arpin C, Noury P, Quentin C. Clinical strain of *Pseudomonas aeruginosa* carrying a *bla* (TEM-21) gene located on a chromosomal interrupted TnA type transposon. *Antimicrob Agents Chemother* 2002;46:3624-6.
- Arpin C, Labia R, Dubois V, Noury P, Souquet M, Quentin C. TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of *Enterobacter cloacae*. *Antimicrob Agents Chemother* 2002;46:1183-9.
- Arpin C, Dubois V, Coulange L, Andre C, Fischer I, Noury P, Grobost F, Brochet JP, Jullin J, Dutilh B, Larrivet G, Lagrange I, Quentin C. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. *Antimicrob Agents Chemother* 2003;47:3506-14.
- Albertini MT, Benoit C, Berardi L, Berrouane Y, Boisvion A, Cahen P, Cattoen C, Costa Y, Darchis P, Deliere E, Demontrond D, Eb F, Golliot F, Grise G, Harel A, Koeck JL, Lepennec MP, Malbrunot C, Marcollin M, Maugat S, Nouvellon M, Pangon B, Ricouart S, Roussel-Delvallez M, Vachee A, Carbonne A, Marty L, Jarlier V. Surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. *Microbiology Surveillance Network of Northern France. J Hosp Infect* 2002;52:107-13.
- Talon D, Bailly P, Bertrand X, Thouverez M, Mulin B, and members of Réseau Franc-Comtois de Lutte contre les infections nosocomiales. Clinical and molecular epidemiology of chromosome-mediated resistance to third-generation cephalosporins in *Enterobacter* isolates in Eastern France. *Clin Microbiol Infect* 2000;6:376-84.
- Bertrand X, Thouverez M, Bruand L, Bonnin M, Cellier-Julienne G, Chantelat P, Chaput C, Febvre C, Louvrier E, Mermet F, Penin B, Tronel H, Talon D. *Escherichia coli*: sensibilité aux β -lactamines et diversité génomique des souches isolées en Franche-Comté. *Med Mal Infect* 2002;32:8-18.